Zealand Pharma Zeydovio gets positive EU panel opinion
Zealand Pharma said the EMA’s Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of its short bowel syndrome drug candidate Zeydovio (OMXCOP: ZEAL).
Zealand Pharma OMXCOP:ZEAL said on Friday that the Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of its drug candidate Zeydovio for the treatment of short bowel syndrome. The company said the positive opinion marks the first major advancement in the process.